中国医学科学院学报2018，Vol.40Issue(2)：264-267,4.DOI:10.3881/j.issn.1000-503X.2018.02.018
60min利妥昔单抗快速输注治疗成人B细胞淋巴瘤的安全性:一项单中心、单臂临床试验
Safety of A 60-minute Rituximab Rapid Infusion Protocol for Adult B-cell Lymphoma Patients: A Single-center Single Arm Clinical Trail
刘双娇 1孟伟 1张艳彬1
作者信息
- 1. 中国医学科学院 北京协和医学院 北京协和医院血液科,北京100730
- 折叠
摘要
Abstract
Objective To investigate the safety of a 60-minute rituximab rapid infusion protocol in the maintenance therapy for Chinese B-cell lymphoma patients (including the elderly) and to discuss the feasibility of rituximab treatment in outpatient departments or daily wards.Methods This prospective study enrolled 820 patients diagnosed with B cell lymphoma in the Department of Hematology of Peking Union Medical College Hospital from February 2015 to July 2016.From the second chemotherapy cycle,rituximab was infused within 60 minutes (100 mg/h over the first 15 minutes and the remaining dose given over 45 minutes,there was no maximum infusion rate,and 700 mg/h was acceptable),and the adverse reactions were recorded.Comparison was done between patients ＜ 65 years and ≥65 years.Results The overall adverse reaction rate was 4.20％ and no grade 4 or higher adverse reactions were recorded.The adverse reaction rate in the elderly patients was not significantly elevated.Conclusion For Chinese patients (including the elderly) with B cell lymphoma,the 60-minute rapid infusion of rituximab (beyond the first cycle) is a safe treatment option with low adverse reaction rate.关键词
淋巴瘤/利妥昔单抗/60min快速输注Key words
lymphoma/rituximab/60-minute rapid infusion分类
医药卫生引用本文复制引用
刘双娇,孟伟,张艳彬..60min利妥昔单抗快速输注治疗成人B细胞淋巴瘤的安全性:一项单中心、单臂临床试验[J].中国医学科学院学报,2018,40(2):264-267,4.
